Shares of Antigenics Inc. (Nasdaq:AGEN) rose since the opening bell Wednesday. The stock ended up +$1.12 at $2.54 on above average volume after seeing a day high of $3.34. The biotechnology company is focused on developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Today, they added to the sharp gains it had after the company presented interim survival data from a study of Oncophage on Monday. The stock is now trading at a new high for the year.

On Monday, Antigenics annouced that patients with kidney cancer at intermediate risk of disease recurrence showed about 46 percent lower risk of death when treated with the cancer vaccine, Oncophage.

Shares of the company have shot up more than four-fold since its Friday's close of 73 cents.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

---

Add this page to your favorite Social Bookmarking websites